Literature DB >> 22640592

Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010.

L R Petersen1, P J Carson2, B J Biggerstaff1, B Custer3, S M Borchardt2, M P Busch3.   

Abstract

West Nile virus (WNV) was first recognized in the USA in 1999. We estimated the cumulative incidence of WNV infection in the USA from 1999 to 2010 using recently derived age- and sex-stratified ratios of infections to WNV neuroinvasive disease (WNND) and the number of WNND cases reported to national surveillance. We estimate that over 3 million persons have been infected with WNV in the USA, with the highest incidence rates in the central plains states. These 3 million infections would have resulted in about 780 000 illnesses. A substantial number of WNV infections and illnesses have occurred during the virus' first decade in the USA.

Entities:  

Mesh:

Year:  2012        PMID: 22640592      PMCID: PMC9151873          DOI: 10.1017/S0950268812001070

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  24 in total

1.  Irrigated agriculture is an important risk factor for West Nile virus disease in the hyperendemic Larimer-Boulder-Weld area of north central Colorado.

Authors:  Lars Eisen; Christopher M Barker; Chester G Moore; W John Pape; Anna M Winters; Nicholas Cheronis
Journal:  J Med Entomol       Date:  2010-09       Impact factor: 2.278

2.  Use of hospital discharge data to evaluate notifiable disease reporting to Colorado's Electronic Disease Reporting System.

Authors:  Tegan K Boehmer; Jennifer L Patnaik; Steven J Burnite; Tista S Ghosh; Ken Gershman; Richard L Vogt
Journal:  Public Health Rep       Date:  2011 Jan-Feb       Impact factor: 2.792

3.  An update on the potential of north American mosquitoes (Diptera: Culicidae) to transmit West Nile Virus.

Authors:  Michael J Turell; David J Dohm; Michael R Sardelis; Monica L Oguinn; Theodore G Andreadis; Jamie A Blow
Journal:  J Med Entomol       Date:  2005-01       Impact factor: 2.278

4.  Irrigation linked to a greater incidence of human and veterinary West Nile virus cases in the United States from 2004 to 2006.

Authors:  Maureen C Gates; Raymond C Boston
Journal:  Prev Vet Med       Date:  2009-01-30       Impact factor: 2.670

5.  Hydrologic conditions describe West Nile virus risk in Colorado.

Authors:  Jeffrey Shaman; Jonathan F Day; Nicholas Komar
Journal:  Int J Environ Res Public Health       Date:  2010-02-11       Impact factor: 3.390

6.  Geographic factors contributing to a high seroprevalence of West Nile virus-specific antibodies in humans following an epidemic.

Authors:  Beth K Schweitzer; Wayne L Kramer; Anthony R Sambol; Jane L Meza; Steven H Hinrichs; Peter C Iwen
Journal:  Clin Vaccine Immunol       Date:  2006-03

7.  The role of hydrogeography and climate in the landscape epidemiology of West Nile virus in New York State from 2000 to 2010.

Authors:  Michael G Walsh
Journal:  PLoS One       Date:  2012-02-06       Impact factor: 3.240

8.  Economic cost analysis of West Nile virus outbreak, Sacramento County, California, USA, 2005.

Authors:  Loren M Barber; Jerome J Schleier; Robert K D Peterson
Journal:  Emerg Infect Dis       Date:  2010-03       Impact factor: 6.883

9.  Rapid determination of HLA B*07 ligands from the West Nile virus NY99 genome.

Authors:  A S De Groot; C Saint-Aubin; A Bosma; H Sbai; J Rayner; W Martin
Journal:  Emerg Infect Dis       Date:  2001 Jul-Aug       Impact factor: 6.883

10.  Ecological factors associated with West Nile virus transmission, northeastern United States.

Authors:  Heidi E Brown; James E Childs; Maria A Diuk-Wasser; Durland Fish
Journal:  Emerg Infect Dis       Date:  2008-10       Impact factor: 6.883

View more
  90 in total

Review 1.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

Review 2.  The innate immune playbook for restricting West Nile virus infection.

Authors:  Kendra M Quicke; Mehul S Suthar
Journal:  Viruses       Date:  2013-10-30       Impact factor: 5.048

3.  West Nile virus-associated acute flaccid paralysis.

Authors:  Ashely Alker
Journal:  BMJ Case Rep       Date:  2015-05-02

4.  Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines.

Authors:  Melissa N Garcia; Anne M Hause; Christopher M Walker; Jordan S Orange; Rodrigo Hasbun; Kristy O Murray
Journal:  Viral Immunol       Date:  2014-07-25       Impact factor: 2.257

5.  Drought and immunity determine the intensity of West Nile virus epidemics and climate change impacts.

Authors:  Sara H Paull; Daniel E Horton; Moetasim Ashfaq; Deeksha Rastogi; Laura D Kramer; Noah S Diffenbaugh; A Marm Kilpatrick
Journal:  Proc Biol Sci       Date:  2017-02-08       Impact factor: 5.349

Review 6.  The continued threat of emerging flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Nat Microbiol       Date:  2020-05-04       Impact factor: 17.745

Review 7.  Risk factors for West Nile virus infection and disease in populations and individuals.

Authors:  Ruth R Montgomery; Kristy O Murray
Journal:  Expert Rev Anti Infect Ther       Date:  2015-01-30       Impact factor: 5.091

8.  Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.

Authors:  Benjamin K Quintel; Archana Thomas; Danae E Poer DeRaad; Mark K Slifka; Ian J Amanna
Journal:  Vaccine       Date:  2018-12-31       Impact factor: 3.641

9.  A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.

Authors:  Amelia K Pinto; Justin M Richner; Elizabeth A Poore; Pradnya P Patil; Ian J Amanna; Mark K Slifka; Michael S Diamond
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

10.  Role of the Vector in Arbovirus Transmission.

Authors:  Michael J Conway; Tonya M Colpitts; Erol Fikrig
Journal:  Annu Rev Virol       Date:  2014-06-02       Impact factor: 10.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.